Roche Wins CE Mark For First Blood-Based IVD Immunoassay Identifying ApoE4 Genetic Variant Linked To Up To 60% Of Diagnosed Alzheimer's Disease Cases
The Elecsys ApoE4 test is the first CE marked in-vitro diagnostic immunoassay to identify individuals carrying the ApoE4 genetic variant using a simple blood sample.
The test offers a fast, reliable and accessible option to rapidly differentiate between carriers and non-carriers.
The test eliminates the need for confirmatory genetic testing in the proportion of Alzheimer's patients who do not carry the ApoE4 variant.
Login to comment